Fate Therapeutics (FATE) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
Tweet
Share
E-mail
Get Alerts FATE Hot Sheet
Join SI Premium – FREE
Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27).
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Collegium Pharma (COLL) Tops Q3 EPS by 10c; Offers Guidance
- IQStel posts $106M in Q3 revenue, nine-month sales rise 35%
- Medicis Pharmaceutical Corp. (MRX) Tops Q3 EPS by 45c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
